Submit RFI/RFP
Category

news5

Biomapas receives Knowledge Economy Company 2016 award

By | news5

26th January, 2016 Biomapas representatives attended the Knowledge Economy Forum award ceremony at the Presidential Palace of the Republic of Lithuania. The Knowledge Economy Company awards are granted each year from 2004 in order to honor the most progressive and innovative companies operating in Lithuania, creating high value-added products or services. The awards are patronized by the President of the Republic of Lithuania Dalia Grybauskaitė.

Read More

Implementation of ISO 9001 and 13485 standards: what does it bring to company and clients?

By | news5

Compliance with high quality standards is a non-negotiable performance parameter in Pharmaceutical and Medical Device industries. During 2016, Biomapas was re-certified according to the newest ISO 9001 standard version. Moreover, at the beginning of 2017, ISO 13485 implementation into BIOMAPAS Quality Management System was initiated. We discussed the influence of current changes to the whole company and its quality management with Egidija Pauriene, MD, Quality Assurance Director.

Read More

Lithuania intends to take on the RMS role from UK for 70 Mutual Recognition and Decentralised Procedures

By | news5

The United Kingdom (UK) submitted on 29 March 2017 the notification of its intention to withdraw from the Union pursuant to Article 50 of the Treaty on European Union (EU). This means that the United Kingdom will become a ‘third country’ from 30 March 2019.
According to Directive 2001/83/EC the reference member state (RMS) must be a member of the EU. As a result the RMS role in Mutual Recognition and Decentralised Procedures (MRP/DCP) must be transferred to an EU country.

Read More
Egle Pavyde, Mpharm, PhDc, Business Development Director

CIS and Eurasian Economic Union: high Pharma industry interest and new legislation

By | news5

The interest of pharmaceutical companies in expanding business across CIS region has been constantly growing. For the same reason, Biomapas has expanded presence and now covers the whole CIS region, providing core services: clinical research, regulatory affairs, pharmacovigilance.
Associate Director Business Development Egle Pavyde, shares some thoughts about region peculiarities, recent legislation changes and Biomapas experience providing RA and PV services in CIS.

Read More

Biomapas: Improving the Document Review Process

By | news5

Biomapas currently covers 64 countries across Europe, CIS and MENA regions. Being able to provide clinical trial, regulatory affairs, medical writing and vigilance solutions to all of these countries requires us to have a large repertoire of native speakers on staff.

Since providing top quality work to our customers has always been of paramount importance for Biomapas, we needed a way to ensure document accuracy, and therefore decided to look at proofreading software to help us maintain quality.

Read More
Audrius Sveikata, MD, PhD, Chief Executive Officer

AICROS Annual Meeting: insights and future perspectives

By | news5

The Association of International Clinical Research Organizations (AICROS) is a network of small to mid-size CROs, which provide clinical research services to the pharmaceutical, biotech and medtech industries. Biomapas joined AICROS in 2014 and since then has been an active member of the association. On the 20-22 February, Biomapas’ CEO Audrius Sveikata participated in the AICROS Annual meeting, which took place in Tel Aviv, Israel. Audrius shared his insights about the meeting and the future perspectives of the association.

Read More

Biomapas Receives CIR (French Research Tax Credit) Accreditation

By | News, news5

Biomapas a annoncé récemment avoir reçu de la part du Ministère de l’enseignement supérieur et de la recherche l’accréditation Crédit d’Impôt Recherche (CIR) pour une période de trois ans.

Biomapas has recently announced that it has received Research Tax Credit (Crédit d’Impôt Recherche; CIR) accreditation for a three-year period from the French Ministry of Higher Education and Research.
.

Read More